Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking BioLife’s cryopreservation revenue or CGT logistics risks in a 300-page filing can drain hours. BioLife Solutions insider trading Form 4 transactions hide in dense tables, while critical 8-K updates on clinical-trial shipments surface without warning. If you have ever wondered, “How do I locate BioLife Solutions’ quarterly earnings report 10-Q filing in seconds?” Stock Titan delivers the answer.
Our platform ingests every submission the moment it hits EDGAR and feeds it to an AI engine that turns jargon into clarity. Need a BioLife Solutions annual report 10-K simplified? We highlight consumable sales growth, supply-chain quality metrics, and major risk factors. Looking for BioLife Solutions Form 4 insider transactions real-time? Instant alerts show which executives added shares. The AI also tags each BioLife Solutions proxy statement executive compensation section, unpacks option grants, and links them to performance goals. From BioLife Solutions earnings report filing analysis to a plain-English explainer of every BioLife Solutions 8-K material events explained, the information arrives ready to use.
Professionals rely on these insights to compare consumable-driven gross margins, monitor BioLife Solutions executive stock transactions Form 4 before therapy milestones, and evaluate liquidity through each BioLife Solutions SEC filings explained simply. Whether you are understanding BioLife Solutions SEC documents with AI for the first time or fine-tuning a DCF model, Stock Titan’s real-time coverage, AI-powered summaries, and historical archive of every filing form provide the edge you need—no more hunting through PDFs for the numbers that move CGT markets.
BIOLIFE SOLUTIONS, INC. (BLFS) Rule 144 notice reports proposed sale of 714 common shares by a holder through Morgan Stanley Smith Barney on 09/15/2025 on NASDAQ, with an aggregate market value listed as $18,214.14 and total shares outstanding shown as 47,905,265. The securities were acquired as restricted stock units on 09/08/2025 from the issuer and the filing records payment or settlement on that same date.
The filer disclosed three prior sales by the same person in the past three months: 711 shares via a 10b5-1 sale on 06/16/2025 for $15,805.53, 198 shares on 07/07/2025 for $4,409.46, and 219 shares on 08/26/2025 for $5,571.36. The filing includes a representation that the seller is not aware of undisclosed material adverse information and notes the option to rely on a 10b5-1 plan; no plan adoption date or signature block details are present in the provided content.
Insider sale under pre-existing plan: Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, reported a sale of 531 shares of BioLife common stock on 08/26/2025 at a price of $25.44 per share. The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted on 02/24/2022 to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported sale, the filing shows Mr. Mathew beneficially owns 352,051 shares directly. The Form 4 was signed on 08/28/2025 and the filer indicated the transaction was executed under the 10b5-1 plan.
Karen A. Foster, Chief Quality and Operations of BioLife Solutions Inc. (BLFS), reported a sale of 413 shares of the company's common stock on 08/26/2025 at a price of $25.44 per share. Following the transaction, Ms. Foster beneficially owns 194,183 shares, held directly.
The filing states the sale was executed under a Rule 10b5-1(c) trading plan adopted by the reporting person on 02/24/2022 to satisfy tax withholding obligations related to the vesting of restricted stock. The Form 4 is signed and dated 08/28/2025.
Sean Werner, Chief Technology Officer of BioLife Solutions, sold 111 shares of the company's common stock on 08/26/2025 at $25.44 per share under a pre-existing Rule 10b5-1(c) trading plan. The Form 4 shows the sale was to satisfy tax withholding obligations tied to the vesting of restricted stock and the reporting person retained 26,384 shares of common stock after the transaction. The filing is signed by Sean Werner on 08/28/2025 and indicates the Form is filed by one reporting person.
Insider sale under 10b5-1 plan: Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 590 shares of BioLife Solutions Inc. (BLFS) on 08/26/2025 at a price of $25.44 per share. After the sale, Mr. Wichterman beneficially owned 185,218 shares, held directly. The filing states the sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 02/24/2022 to satisfy tax withholding obligations arising from the vesting of restricted stock. The Form 4 is signed by the reporting person on 08/28/2025.
Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 219 shares of common stock on 08/26/2025 at $25.44 per share under a pre-established Rule 10b5-1(c) plan. The filing states the sale was executed to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported transaction, the reporting person beneficially owned 78,304 shares of BioLife Solutions common stock, held directly.
The sale was made pursuant to a 10b5-1 trading plan adopted 02/24/2022, which the filer checked on the form to indicate pre-planned execution; the Form 4 is signed and dated 08/28/2025.
Insider sale under a pre-established plan: Todd Berard, Chief Marketing Officer of BioLife Solutions Inc. (BLFS), reported the sale of 354 shares of common stock on 08/26/2025 at a price of $25.44 per share. After the transaction, Berard beneficially owned 134,264 shares, held directly. The filing states the sale was made pursuant to a Rule 10b5-1(c) trading plan adopted 02/24/2022 to satisfy tax withholding obligations from restricted stock vesting. The Form 4 is a routine disclosure of a planned sale; no new grants, options, or derivative transactions are reported.
Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 10,000 shares of BLFS common stock on 08/25/2025 at a weighted average price of $25.53 per share (individual trade prices ranged from $25.46 to $25.63). After the sale, the reporting person beneficially owned 124,618 shares. The Form 4 was signed on 08/27/2025 and discloses the sale as a direct disposition. The filer notes the reported price is a weighted average from multiple transactions and offers to provide the number of shares sold at each price upon request.
Form 144 notice for BioLife Solutions, Inc. (BLFS) reports a proposed sale of 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $255,265 and an approximate sale date of 08/25/2025. The shares were acquired on 03/03/2025 as restricted stock that vested under a registered plan and the payment type is recorded as compensation. The filer reports no securities sold in the past three months and includes the required representation that they are not aware of undisclosed material adverse information.
Casdin-related entities reported a 14.0% stake in BioLife Solutions (BLFS), owning 6,707,165 common shares based on 47,905,265 shares outstanding as of July 31, 2025. The shares are held by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin, who together share voting and dispositive power over the reported shares. The Reporting Persons state the shares were purchased for investment using the Fund's working capital and that no borrowed funds were used other than ordinary working capital borrowings. They state no current plans to pursue corporate control changes but reserve the right to recommend actions or cooperate with others to maximize shareholder value.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
